Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$41.89
+0.6%
$40.09
$35.12
▼
$64.16
$187.05B0.716.29 million shs8.72 million shs
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
$164.11
-2.3%
$184.79
$106.37
▼
$212.94
$394.65B1.6540.58 million shs5.75 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$588.09
-0.5%
$542.60
$455.63
▼
$614.23
$25.05B0.49552,484 shs115,399 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+3.18%+7.42%-7.21%-13.62%
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
0.00%+4.74%-9.70%-2.64%-3.46%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%+5.19%+10.89%+16.26%+26.75%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$41.89
+0.6%
$40.09
$35.12
▼
$64.16
$187.05B0.716.29 million shs8.72 million shs
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
$164.11
-2.3%
$184.79
$106.37
▼
$212.94
$394.65B1.6540.58 million shs5.75 million shs
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$588.09
-0.5%
$542.60
$455.63
▼
$614.23
$25.05B0.49552,484 shs115,399 shs
7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.00%+3.18%+7.42%-7.21%-13.62%
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
0.00%+4.74%-9.70%-2.64%-3.46%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
0.00%+5.19%+10.89%+16.26%+26.75%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
2.00
Hold$59.4441.89% Upside
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
2.69
Moderate Buy$216.2031.74% Upside
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2.69
Moderate Buy$676.4015.02% Upside

Current Analyst Ratings Breakdown

Latest PLTR, NVO, and UTHR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/16/2026
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
Set Price Target$248.00
11/16/2026
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
Set Price Target$248.00
11/10/2026
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
Initiated CoverageBuy$200.00
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
DowngradeBuy (B-) ➝ Hold (C+)
11/9/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Initiated CoverageBuy$660.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetOverweight$700.00 ➝ $703.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetBuy$675.00 ➝ $700.00
11/5/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Boost Price TargetOutperform$697.00 ➝ $725.00
11/4/2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
Set Price Target$720.00
11/4/2026
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
Set Price Target$255.00
11/4/2026
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
Reiterated RatingSector Weight
(Data available from 11/16/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$333.65B0.56$4.72 per share8.88$6.58 per share6.37
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
$7.29B54.11$0.67 per share243.28$3.13 per share52.43
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$3.18B7.87$32.82 per share17.92$164.81 per share3.57
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$15.51B$3.9710.5512.141.4333.99%53.52%19.49%2/3/2027 (Estimated)
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
$1.63B$1.43114.8482.883.3950.34%30.49%25.71%2/1/2027 (Estimated)
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$1.33B$26.5022.1918.353.9338.61%19.18%17.07%N/A

Latest PLTR, NVO, and UTHR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
$6.01$5.71-$0.30$5.71$781.14 million$832.50 million
11/2/2026Q3 2026
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
$0.4061$0.44+$0.0339$0.44$2.18 billion$2.31 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
$0.811.94%+21.74%20.40%N/A
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
N/AN/AN/AN/AN/A
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.54
0.84
0.64
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
N/A
7.10
7.10
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
N/A
4.61
4.29

Institutional Ownership

CompanyInstitutional Ownership
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
11.54%
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
45.65%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
94.08%

Insider Ownership

CompanyInsider Ownership
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
0.07%
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
9.53%
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
8.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Novo Nordisk A/S stock logo
NVO
Novo Nordisk A/S
69,5054.47 billion4.46 billionOptionable
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
4,4292.40 billion2.17 billionOptionable
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
1,40042.59 million38.93 millionOptionable

Recent News About These Companies

FY2026 Earnings Forecast for UTHR Issued By HC Wainwright
Analysts Issue Forecasts for UTHR FY2026 Earnings
HC Wainwright Initiates Coverage on United Therapeutics (NASDAQ:UTHR)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Novo Nordisk A/S stock logo

Novo Nordisk A/S NYSE:NVO

$41.89 +0.26 (+0.63%)
As of 11:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products; and with Korro Bio, Inc. for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Palantir Technologies stock logo

Palantir Technologies NASDAQ:PLTR

$164.11 -3.88 (-2.31%)
As of 11:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates under the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, and Nathan Dale Gettings in 2003 and is headquartered in Denver, CO.

United Therapeutics stock logo

United Therapeutics NASDAQ:UTHR

$588.08 -3.09 (-0.52%)
As of 11:39 AM Eastern
This is a fair market value price provided by Massive. Learn more.

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.